In a filing, Rocket Pharmaceuticals Inc revealed its insider Patel Kinnari unloaded Company’s shares for reported $64305.0 on Feb 21 ’25. In the deal valued at $10.58 per share,6,078 shares were sold. As a result of this transaction, Patel Kinnari now holds 444,103 shares worth roughly $4.16 million.
Then, Wilson Martin sold 3,222 shares, generating $34,089 in total proceeds. Upon selling the shares at $10.58, the General Counsel now owns 150,696 shares.
Before that, Militello John sold 2,737 shares. Rocket Pharmaceuticals Inc shares valued at $28,957 were divested by the insider at a price of $10.58 per share. As a result of the transaction, Militello John now holds 65,757 shares, worth roughly $0.62 million.
Wedbush initiated its Rocket Pharmaceuticals Inc [RCKT] rating to an Outperform in a research note published on December 30, 2024; the price target was $32. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. Scotiabank began covering RCKT with “Sector outperform” recommendation on October 16, 2024. Goldman started covering the stock on April 02, 2024. It rated RCKT as “a Neutral”.
Price Performance Review of RCKT
On Tuesday, Rocket Pharmaceuticals Inc [NASDAQ:RCKT] saw its stock fall -6.87% to $9.36. Over the last five days, the stock has lost -13.33%. Rocket Pharmaceuticals Inc shares have fallen nearly -25.54% since the year began. Nevertheless, the stocks have fallen -67.72% over the past one year. While a 52-week high of $31.47 was reached on 01/02/25, a 52-week low of $9.33 was recorded on 02/25/25. SMA at 50 days reached $11.12, while 200 days put it at $17.33.
Levels Of Support And Resistance For RCKT Stock
The 24-hour chart illustrates a support level at 9.00, which if violated will result in even more drops to 8.63. On the upside, there is a resistance level at 9.95. A further resistance level may holdings at 10.53. The Relative Strength Index (RSI) on the 14-day chart is 33.92, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.41, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 93.72%. Stochastics %K at 31.34% indicates the stock is a holding.
The most recent change occurred on October 24, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $65 price target.
